Health & Medical Archives | Page 19 of 242 | Be Korea-savvy

Archive by category Health & Medical

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers

VANCOUVER, British Columbia, June 17, 2024 (Korea Bizwire) – Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for ZW171, [...]

ElmediX Plans Series A Round Based on Strong Signals in a Clinical Study for Pancreatic Cancer Patients at the University Hospital Antwerp (Belgium)

ElmediX Plans Series A Round Based on Strong Signals in a Clinical Study for Pancreatic Cancer Patients at the University Hospital Antwerp (Belgium)

A novel and innovative approach to treating metastasized cancer, starting with the very lethal grade 4 pancreatic cancer.  Earlier this year, scientists from Columbia University in New York demonstrated that the growth rate of pancreatic cancer, measured in patients’ blood using CA19-9 as biomarker, determines survival chances and can be used as a quick way to assess treatment [...]

From Awareness to Action on Global Fatty Liver Day

From Awareness to Action on Global Fatty Liver Day

Global Liver Institute Unites the Field in Times of Name Changes and New Treatments WASHINGTON, Jun. 13 (Korea Bizwire) — Today marks the seventh annual Global Fatty Liver Day (formerly International NASH Day), led by Global Liver Institute (GLI) with the theme “Act Now, Screen Today.” This campaign underscores the crucial need for early identification and treatment [...]

Alta Semper Acquires Allmed Group to Deliver Advanced Blood Purification and Dialysis Solutions Worldwide

Alta Semper Acquires Allmed Group to Deliver Advanced Blood Purification and Dialysis Solutions Worldwide

Alta Semper acquires Allmed Group to deliver advanced blood purification and dialysis solutions worldwide London, UK, 13th of June 2024; Allmed Group (“Allmed” or “the Company“), a producer of end-to-end blood purification and haemodialysis solutions, announced today that Alta Semper Capital (“Alta Semper”), a London-based private equity firm specialising in impact investments primarily in the healthcare sector across [...]

Smith+Nephew Personalizes Robotic-assisted Surgery for Patients and Surgeons with Launch of CORIOGRAPH™ Pre-Operative Planning and Modeling Services Exclusively for the CORI™ Surgical System

Smith+Nephew Personalizes Robotic-assisted Surgery for Patients and Surgeons with Launch of CORIOGRAPH™ Pre-Operative Planning and Modeling Services Exclusively for the CORI™ Surgical System

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of its new CORIOGRAPH Pre-Operative Planning and Modeling Services, providing an unparalleled, personalized solution for surgeons and patients across partial and total knee arthroplasty procedures. It is exclusively for use with the CORI Surgical System – the only orthopaedic robotic-assisted system to offer [...]

Junshi Biosciences Announces Phase 3 Study of Toripalimab Combined with Bevacizumab for the First-line Treatment of Advanced Hepatocellular Carcinoma Meets Primary Endpoint

Junshi Biosciences Announces Phase 3 Study of Toripalimab Combined with Bevacizumab for the First-line Treatment of Advanced Hepatocellular Carcinoma Meets Primary Endpoint

SHANGHAI, Jun. 11 (Korea Bizwire) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the primary endpoints of progression-free survival (“PFS,” based on independent radiographic review) and overall survival (“OS”) of a multi-center, randomized, open-label, [...]

Bright Peak Therapeutics Announces $90 Million in Series C Financing to Advance First-in-Class PD1-IL18 Immunoconjugate Program Into Clinical Trials

Bright Peak Therapeutics Announces $90 Million in Series C Financing to Advance First-in-Class PD1-IL18 Immunoconjugate Program Into Clinical Trials

– Lead Program, BPT567, will be the first PD1-IL18 immunoconjugate to enter the clinic; Phase 1/2a study in solid tumors expected to begin in 2H 2024 – – Financing led by Johnson & Johnson with participation by new and existing investors – BASEL, Switzerland and SAN DIEGO, June 11, 2024 (Korea Bizwire) – Bright Peak Therapeutics, [...]

PAP Therapy Reduces Hospitalizations by 31% and ER Visits by 23% for People with Obstructive Sleep Apnea and Comorbid Insomnia

PAP Therapy Reduces Hospitalizations by 31% and ER Visits by 23% for People with Obstructive Sleep Apnea and Comorbid Insomnia

ResMed studies presented at SLEEP 2024 also revealed a 17% prevalence of insomnia among adults in North America, Latin America, and the Caribbean, and a higher rate of depression in women with OSA SAN DIEGO, June 10, 2024 (Korea Bizwire) – In collaboration with leading medical researchers from around the world, ResMed (NYSE: RMD, ASX: [...]

Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer

Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer

Pursuant to the terms of the licensing agreement between Zymeworks and BeiGene, Zymeworks is entitled to receive an $8 million milestone payment from BeiGene and remains eligible to receive up to $164 million based on additional milestones plus royalties on product sales A Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) [...]

Boehringer Ingelheim’s Survodutide Shows Breakthrough Improvement in Liver Fibrosis with No Worsening of MASH in 64.5% of Patients with F2 and F3 Fibrosis

Boehringer Ingelheim’s Survodutide Shows Breakthrough Improvement in Liver Fibrosis with No Worsening of MASH in 64.5% of Patients with F2 and F3 Fibrosis

News builds on previously announced primary endpoint, which showed up to 83.0% of adults achieved statistically significant improvement in metabolic dysfunction-associated steatohepatitis (MASH) versus placebo (18.2%). New data on the secondary endpoint shows up to 52.3% of adults with fibrosis stages F1, F2 and F3 had improvement in fibrosis due to MASH.1 Additional sub-analysis shows [...]